Scientific Considerations for Potential Addition of Uterine Cancer to the List of Covered Conditions by the World Trade Center Health Program
Table of contents

I. Executive Summary .................................................................................................................................................. 2

II. Background .............................................................................................................................................................. 3
    A. Procedures for Adding Cancers for Coverage in the WTC Health Program ................................................. 3
    B. Uterine Cancer: Definition, Types, and Risk Factors ....................................................................................... 4
    C. Previous Consideration of Uterine Cancer by the WTC Health Program ...................................................... 6

III. WTC Health Program Evaluation of Available Evidence Regarding Uterine Cancer Among 9/11 Exposed Populations ........................................................................................................................................ 6
    A. Method 1 – Epidemiologic Studies of September 11, 2001 Exposed Populations ........................................ 7
    B. Method 2 – Established Casual Association ................................................................................................... 14
    C. Method 3 – Review of Evaluations of Carcinogenicity in Humans ................................................................. 15

IV. Additional Considerations ...................................................................................................................................... 24

V. WTC Health Program’s Actions after Receipt of the STAC Recommendation .................................................... 27

VI. References .............................................................................................................................................................. 28
I. Executive Summary

The World Trade Center (WTC) Health Program provides medical monitoring and treatment benefits for health conditions on the List of WTC-Related Health Conditions (the List). The List currently includes aerodigestive disorders, mental health conditions, musculoskeletal disorders, and cancers. The List was established in the Zadroga Act and new health conditions may be added to the List by rulemaking. In addition to the Program’s regulatory provisions in 42 C.F.R. Part 88, the WTC Health Program Policy and Procedures for Adding Types of Cancer to the List of WTC-Related Health Conditions governs the evaluation of evidence supporting the potential addition of a type of cancer to the List.

Uterine cancer is currently the only type of cancer not included in the WTC Health Program’s List of WTC-Related Conditions. In September 2020, the WTC Health Program received a submission to add uterine cancer to the List. The medical basis for the submission was the contributing role of endocrine disrupting chemicals (EDCs) on the incidence rate of uterine cancers. Although this submission did not meet the Program’s petition requirements, the Administrator instructed WTC Health Program staff to review the evidence for uterine carcinogenicity by EDCs and other 9/11 agents. This document provides the WTC Health Program’s assessment of the currently available evidence to support adding uterine cancer to the List.

In addition to directing the Science Team to assess the available evidence supporting the addition of uterine cancer to the List, the Administrator is seeking the advice of the Scientific/Technical Advisory Committee (STAC) for a recommendation regarding whether there is a reasonable basis for adding uterine cancer to the List. The STAC is given up to 180 days to provide the recommendation. The Administrator will evaluate the STAC’s advice and will take an appropriate action not later than 90 days after receipt of the recommendation.
II. Background

The WTC Health Program provides medical monitoring and treatment benefits for health conditions on the List of WTC-Related Health Conditions (List). The List currently includes aerodigestive disorders, mental health conditions, musculoskeletal disorders, and cancers. Currently, uterine cancer is the only type of cancer not included on the List.¹

Uterine cancer is often referred to as endometrial cancer because more than 90 percent of cases occur in the endometrium. Known risk factors for uterine cancer include endometrial hyperplasia, hormone therapy with estrogen, selective estrogen receptor modulators, and obesity. Protective factors include increasing parity (number of pregnancies) and lactation, hormonal contraceptives, physical activity, and smoking.

A subtype of uterine cancer, uterine sarcoma, is covered as a rare cancer—those cancers that have an incidence rate of less than 15 cases per 100,000 per year in the U.S. based on 2005-2009 average annual data age-adjusted to the 2000 U.S. population.² In addition, uterine cancers that arise from the use of tamoxifen to treat a WTC-certified cancer may be covered as a medically associated condition (MAC).

A. Procedures for Adding Cancers for Coverage in the WTC Health Program

The James Zadroga 9/11 Health and Compensation Act of 2010 (Zadroga Act) established the List and permits the addition of more health conditions through rulemaking. The Zadroga Act provides two pathways to initiate the process of adding a health condition, including types of cancer, to the List: (1) the Administrator of the WTC Health Program initiates the rulemaking process and publishes a proposed rule or requests a recommendation from the STAC at his discretion; or (2) the Administrator initiates the process after receiving a petition from an interested party.³

In addition to the Program’s regulatory provisions in 42 C.F.R. Part 88, the WTC Health Program Policy and Procedures for Adding Types of Cancer to the List of WTC-Related Health Conditions governs the evaluation of evidence supporting the potential addition of a type of cancer to the List.⁴ The Policy and Procedures establishes that a review of the evidence must demonstrate fulfillment of at least one of four methods as basis to propose adding a condition to the List:

Method 1 – Epidemiologic studies of September 11, 2001 exposed populations

The WTC Health Program evaluates the “weight of evidence” from peer-reviewed, published, epidemiologic studies of 9/11-exposed populations, by following four following criteria of Bradford Hill’s guidelines for assessing causation:⁵

a. Strength of the association between a 9/11 exposure and a type of cancer (including the precision of the risk estimate);

b. Consistency of the findings across multiple studies;

c. Biological gradient, or dose-response relationships between 9/11 exposures and the type of cancer; and

d. Plausibility and coherence with known facts about the biology of the type of cancer.
Method 2 – Established casual association

A type of cancer may be added to the List if there is well-established scientific support published in multiple epidemiologic studies for a causal association between that cancer and a condition already on the List of WTC-Related Health Conditions.

Method 3 – Review of evaluations of carcinogenicity in humans

A type of cancer may be added to the List under Method 3 only if both of the following criteria are satisfied:

- **3A. Published exposure assessment information.** A 9/11 agent included in the Inventory of 9/11 Agents is identified; and

- **3B. Evaluation of carcinogenicity in humans from scientific studies.** The National Toxicology Program (NTP) has determined that the 9/11 agent is known to be a human carcinogen or is reasonably anticipated to be a human carcinogen, and the International Agency for Research on Cancer (IARC) has determined there is sufficient or limited evidence that the 9/11 agent causes a type of cancer.

Method 4 – Review of information provided by the WTC Health Program Scientific/Technical Advisory Committee (STAC)

A type of cancer may be added to the List if the STAC provides a reasonable basis for adding it.

B. Uterine Cancer: Definition, Types, and Risk Factors

Cancer of the uterine corpus (uterine cancer) is a type of cancer that begins to develop in the uterus. The uterus is the hollow, pear-shaped pelvic organ where a fetus develops. Uterine cancer is often referred to as endometrial cancer because more than 90 percent of cases occur in the endometrium (lining of the uterus); most of the remainder of uterine cancers originate in the myometrial muscle or, less commonly, the endometrial stroma.

Table 1 lists all subtypes of uterine cancer and their codes, according to the International Classification of Diseases, 10th Edition (ICD-10).

<table>
<thead>
<tr>
<th>ICD-10 Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>C54</td>
<td>Malignant neoplasm of corpus uteri</td>
</tr>
<tr>
<td>C54.0</td>
<td>Malignant neoplasm of isthmus uteri</td>
</tr>
<tr>
<td>C54.1</td>
<td>Malignant neoplasm of endometrium</td>
</tr>
<tr>
<td>C54.2</td>
<td>Malignant neoplasm of myometrium</td>
</tr>
<tr>
<td>C54.3</td>
<td>Malignant neoplasm of fundus uteri</td>
</tr>
</tbody>
</table>
According to the American Cancer Society, in 2021 an estimated 66,570 cases of uterine cancer will be diagnosed in the United States and 12,940 women are expected to die from the disease. Endometrial cancer is the fourth most common cancer in U.S. women after cancers of the breast, lung/bronchus, and colon/rectum. The incidence peaks between ages 60 and 70 years, but 2 to 5 percent of cases occur before age 40 years.

The National Cancer Institute (NCI) identifies the following as known factors that increase the risk of uterine cancer and provides a basis for their identification:

- **Endometrial hyperplasia**
  Based on solid evidence in prospective cohort studies, endometrial hyperplasia is associated with concurrent or subsequent development of cancer.

- **Hormone therapy with estrogen: Unopposed estrogen**
  Based on solid evidence in randomized controlled trials, cohort, and case-control studies, unopposed estrogen (estrogen therapy alone without the counterbalancing effects of progesterone) is associated with an increased risk of endometrial cancer. This excess risk can be eliminated by adding continuous progestin to estrogen therapy, but this combination is associated with an increased risk of breast cancer.

- **Selective estrogen receptor modulators (SERMs)**
  Based on solid evidence in multiple randomized controlled trials, use of tamoxifen (a SERM) for more than 2 years is associated with an increased risk of uterine cancer.

- **Obesity**
  Based on solid evidence in multiple randomized controlled trials, being overweight or obese, and adult weight gain are associated with an increased risk of uterine cancer.

NCI also indicates that the following factors that decrease the risk of uterine cancer and provides a basis for their identification:

- **Increasing parity and lactation**
  Based on solid evidence in a prospective cohort study and case-control studies, increased number of pregnancies and duration of lactation are associated with a decreased risk of uterine cancer.

- **Hormonal contraceptives**
  Based on solid evidence in case-control studies and cohort studies, at least 1-year use of oral contraceptives containing estrogen and progesterone decreases uterine cancer risk, proportionate to duration of use.
• **Physical activity**

Based on solid evidence in multiple cohort and case-control studies, increased physical exercise is associated with a decreased risk of uterine cancer.

• **Smoking: Benefits**

Based on evidence in prospective cohort and case-control studies, cigarette smoking is associated with a decreased risk of uterine cancer.

NCI also concluded that the following intervention has adequate evidence of no association with uterine cancer:

• **Fruits, vegetables, and vitamins**

Cohort and case-control studies provide adequate evidence of no association between uterine cancer and diet or vitamin intake.

C. Previous Consideration of Uterine Cancer by the WTC Health Program

To date, the WTC Health Program has received eight submissions to add uterine cancer or uterine cancer subtypes to the List; seven of these submissions did not meet the requirements of the *Policy and Procedures for Handling Submissions and Petitions to Add a Health Condition to the List of WTC-Related Health Conditions* to qualify as petitions. Submission 117 received in 2019 was determined to qualify as a petition (Petition 023); however, following a thorough review and evaluation of published, peer-reviewed epidemiologic evidence in 9/11 populations, the Administrator determined that the evidence was insufficient to add uterine cancer to the List. In September 2020, the WTC Health Program received Submission 166 from the WTC Health Program Clinical Centers of Excellence (CCEs) to add uterine cancer to the List. The basis for the submission was that the WTC Health Program should consider the contributing role of endocrine disrupting chemicals (EDCs) on the incidence rate of uterine cancers. The submission did not meet the criteria to qualify as a petition, since no new medical basis was provided.

Although the submission from the CCEs did not qualify as a petition, the Administrator found that the issues raised regarding the contributing role of EDCs and the low number of women included in study populations with occupational 9/11 exposure merit further consideration. As a result, the Administrator exercised his discretion to initiate the process of deciding whether to propose adding uterine cancer to the List and directed the WTC Health Program’s Science Team to review the available scientific evidence for EDCs causing uterine cancer to determine if it has the potential to provide a basis for a decision on whether to add uterine cancer to the List.

III. WTC Health Program Evaluation of Available Evidence Regarding Uterine Cancer Among 9/11 Exposed Populations

Pursuant to the *Policy and Procedures for Adding Types of Cancer to the List of WTC-Related Health Conditions*, the WTC Health Program conducted a literature review and assessed the available evidence using Methods 1, 2, and 3. The results of that assessment are summarized below:

**Method 1 – Epidemiologic Studies of September 11, 2001 Exposed Populations.** Five relevant peer-reviewed, published, epidemiologic studies were identified and reviewed. The studies do not
provide consistent evidence of elevated uterine cancer incidence or mortality among WTC responders and survivors. The studies also do not report a dose-response relationship between 9/11 exposures and uterine cancer and the study designs may be susceptible to selection bias. As a result, collectively, these studies do not demonstrate a potential to provide a basis for a decision on whether to add uterine cancer to the List.

**Method 2 – Established Casual Association.** A thorough review of the scientific literature found that estrogen-secreting tumors are associated with endometrial cancer, but that these estrogen-secreting tumors are rare. Because estrogen-secreting tumors fall under the category of “rare cancers” in the List, uterine cancer can be added to the List only for members who have a certified estrogen-secreting tumor.

**Method 3 – Review of Evaluations of Carcinogenicity in Humans.** Four EDCs listed in the Inventory of 9/11 Agents are considered carcinogenic to humans by NTP or IARC: (1) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); (2) 2,3,4,7,8-pentachlorodibenzofuran; (3) polychlorinated biphenyls (PCB); and (4) cadmium. None of these agents is considered to have sufficient or even limited evidence of uterine carcinogenicity. Further review of epidemiologic studies published after the NTP and IARC reports did not identify additional evidence of carcinogenicity to the uterus.

A complete discussion of the studies identified, and the Program’s assessment follows.

**A. Method 1 – Epidemiologic Studies of September 11, 2001 Exposed Populations**

The Science Team reviewed the epidemiologic studies of September 11, 2001-exposed populations to determine if the body of evidence has the potential to provide a basis for a decision on whether to add uterine cancer to the List. In general, this review followed five key steps: (1) define the causal questions of interest and develop criteria for study selection; (2) develop a literature search protocol and conduct the search; (3) review, identify, and select the relevant information from available studies; (4) evaluate and integrate the evidence across studies; and (5) synthesize and interpret findings.

The epidemiological studies considered in the evaluation were focused on evaluating the health effects of 9/11 exposures among two groups of people, as described by the Zadroga Act:

- **WTC Responders:** workers or volunteers who provided rescue, recovery, debris cleanup, and related support services on or in the aftermath of the September 11, 2001, attacks for certain amounts of time during the period between September 11, 2001, and July 31, 2002. There are three types of responders: Fire Department of the City of New York (FDNY) Responders, New York City (NYC) General Responders (including New York City Police Department (NYPD)), and Pentagon and Shanksville, PA, Responders.
- **WTC Survivors:** individuals who were present in the NYC Disaster Area in the dust or dust cloud on September 11, 2001; who worked, resided, or attended school, childcare, or adult daycare in the NYC Disaster Area from September 11, 2001, to July 31, 2002; who were eligible for certain residential grants or whose place of employment was eligible for certain grants following the September 11, 2001, attacks.

Some studies considered in this Method have been conducted among enrollees of the WTC Health Registry, a registry developed in 2002 to document and evaluate the long-term physical and mental health effects of 9/11. More than 71,000 responders and survivors voluntarily enrolled in the Registry during 2003-04.
As indicated above, in 2019 the WTC Health Program received a petition to add uterine cancer to the List. At the time, the Administrator instructed the Science Team to search the literature and review the available published, peer-reviewed epidemiologic studies of uterine cancer in 9/11-exposed populations. Databases searched included: CINAHL, Embase, NIOSHTIC-2, ProQuest Health & Safety, PsycINFO, Ovid MEDLINE, Scopus, Toxicology Abstracts/TOXLINE, and WTC Health Program Bibliographic Database. The following keywords were used to conduct the search: endometrial neoplasm, endometrial cancer, endometrial carcinoma, malignant neoplasm of endometrium, adenocarcinoma of endometrium, cancer of the endometrium, uterine neoplasm, malignant neoplasm of corpus uteri, uterine cancer, uterine carcinoma; and the terms: World Trade Center, WTC, September 11, September 11 terrorist attacks. The literature search was conducted in English-language journals on May 23, 2019.

As part of the current assessment, a new literature search using the same search terms and databases as in Petition 023 was conducted on April 19, 2021. In addition to the two articles identified for that Petition, the new search identified one additional epidemiologic article that reports uterine cancer as an outcome. This study reported a case series of cancers identified by the WTC Environmental Health Center, the Clinical Center of Excellence (CCE) for survivors. A total of 2,999 cancer diagnoses (excluding non-melanoma skin cancer) were identified in 2,561 patients. Primary cancer diagnoses identified by a pathology/cytology report, among participants who were enrolled in the CCE between May 2002 and 31 December 2019, were included in the analysis. Among women, 1,305 cancers were identified. Breast cancer (46%) was the most common cancer diagnosis, followed by lung (11%), thyroid (9%), and lymphoma (6%); uterine cancer was found in only 0.76% of all cases. Since this study provided only cancer counts and did not directly assess cancer incidence or mortality, it was not further used in the evaluation.

In addition, the Program is aware of prospective cohort studies being conducted in several 9/11-exposed subpopulations. The studies follow these subpopulations with the intent to compare them with groups of individuals without 9/11 exposures (usually using U.S. or New York state rates) to evaluate cancer incidence (the number of new cases) and cancer mortality. These prospective cohort studies often perform internal comparisons in which higher exposed cohort members are compared with those that have lower exposures. These studies might include findings on uterine cancer incidence or mortality, but unless the abstract, title, or keywords include these findings, they could be missed in literature searches like the one described above. Therefore, published findings from these studies were reviewed to ascertain if they report findings on uterine cancer.

Nine scientific articles were identified and were further reviewed, including the two articles identified through the literature search. Four studies were excluded from further evaluation. Two of them were conducted among men only and are therefore not relevant for uterine cancer outcomes. One study was excluded because even though it identified three police officers who developed uterine cancer after the September 11, 2001 attacks, background rates of uterine cancer in this population were not provided and the Science Team was not able to interpret this finding.

The following six articles were considered relevant and were used for the evaluation. Their main characteristics are summarized on Table 2.
Table 2. Summary of studies included in the evaluation of evidence between 9/11 exposure and uterine cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Study population</th>
<th>Exposure assessment</th>
<th>Outcome</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solan et al. [2013]²²</td>
<td>Prospective cohort cancer incidence study.</td>
<td>20,984 general responders (3,203 women) involved in rescue, recovery, and cleanup efforts at Ground Zero after 9/11.</td>
<td>Self-reported exposures were categorized based on four variables: occupation, extent of exposure to the dust cloud on 9/11, duration working at the site, and work on the debris pile during four time periods.²⁴ An integrated exposure variable was created using a 4-point scale (very high, high, intermediate, and low) based on total time spent working at Ground Zero, exposure to the dust cloud, and work on the debris pile.²⁵</td>
<td>Cases were identified through linkage with state tumor registries in New York, New Jersey, Connecticut, and Pennsylvania. Vital status obtained through linkage with NDI and next-of-kin reports. Cancer SIRs were calculated based on state rates and national rates.</td>
<td>Overall cancer was elevated for all cancer sites combined (SIR=1.15; 95% CI 1.06-1.25). Fewer than six cases of uterine cancer were observed, and no elevated incidence was reported for this type of cancer. No exposure-response results were reported for uterine cancer.</td>
</tr>
<tr>
<td>Stein et al. [2016]²²</td>
<td>Prospective cohort mortality study.</td>
<td>28,918 general responders who worked or volunteered onsite in rescue, recovery, demolition, debris cleanup, or related duties (4,286 women).</td>
<td>9/11 exposure was self-reported in questionnaires. Exposure was categorized as very high, high, intermediate, and low to reflect the intensity and duration of exposure to the dust, smoke, and debris.</td>
<td>Cause of death was ascertained through linkage to the NDI through 12/31/2011.</td>
<td>Overall cancer deaths were not elevated (SMR 0.43, 95% CI 0.39-0.48). No cause specific SMRs were elevated, including cancers of the female genital organs (SMR=0.65, 95% CI 0.08-2.37). An SMR for uterine cancer was not reported. Overall mortality hazard ratios showed no linear trend with exposure.</td>
</tr>
<tr>
<td>Study</td>
<td>Study design</td>
<td>Study population</td>
<td>Exposure assessment</td>
<td>Outcome</td>
<td>Main findings</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Li et al. [2012]</td>
<td>Prospective cohort cancer incidence study.</td>
<td>Enrollees in the WTC Health Registry who were residents of New York State on 9/11 and had no history of cancer at the time of enrollment. A total of 55,778 individuals were eligible for the study, including 21,850 (4,185 women) involved in rescue/recovery and 33,928 (18,922 women) survivors not involved in rescue/recovery.</td>
<td>Classified exposure as high, intermediate, or low, using qualitative descriptions of WTC exposures. Separate analyses were reported for rescue/recovery workers and for survivors and separate results were reported for the period of enrollment through 2006 and from 2007 through 2008.</td>
<td>Cancers were ascertained by linkage to 11 state cancer registries based on the state of residence of the cohort member. Expected numbers of cancers were based on New York state rates.</td>
<td>Among rescue/recovery workers, the SIR for all cancer sites combined in 2007-2008 was not statistically significantly elevated (SIR=1.14; 95% CI 0.99-1.30). Also, among rescue/recovery workers, uterine cancer incidence was not elevated during the early period (less than five cases, SIR=0.97, 95% CI 0.2-2.83), and no cases were reported during the later period. Among survivors, no statistically significantly increased cancer incidence was observed in 2007-2008. Uterine cancer incidence was not elevated during the earlier nor the late period (SIR=1.01, 95% CI 0.58-1.65 and SIR=1.01, 95% CI 0.55-1.69, respectively). Results of analyses to assess the risk of uterine cancer as a function of WTC exposure levels were not presented.</td>
</tr>
<tr>
<td>Li et al. [2016]</td>
<td>Prospective cohort cancer incidence study.</td>
<td>Update of the Li et al. (2012) study. Enrollees in the WTC Health Registry, including 60,339 eligible individuals; 24,863 (5,015 women) rescue/recovery workers and 35,476 (18,845 women) survivors not involved in rescue/recovery. This analysis included enrollees who lived in any of the 11 states selected for cancer registry linkage between 9/11 and December 31, 2011.</td>
<td>Used recalibrated exposure categories based on potential contaminants containing carcinogens. For rescue/recovery workers, they developed a WTC exposure matrix based on date of arrival, duration of work at the site, dates or time period working on the pile, and being near the WTC site.</td>
<td>The analysis focused on cancers occurring from 2007 through 2011. Data were linked to 11 cancer registries as described above.</td>
<td>Overall cancer incidence was statistically significantly greater than the reference population among both rescue/recovery workers (SIR=1.11, 95% CI 1.03-1.20), and survivors (SIR=1.08, 95% CI 1.02-1.15). Uterine cancer incidence was not statistically significantly elevated among rescue/recovery workers nor among survivors (observed uterine cancers=8, SIR=0.82, 95% CI 0.35-1.62 and observed uterine cancers=37, SIR=1.03, 95% CI 0.72-1.41, respectively). Comparisons among exposure groups were not reported for uterine cancer.</td>
</tr>
<tr>
<td>Study</td>
<td>Study design</td>
<td>Study population</td>
<td>Exposure assessment</td>
<td>Outcome</td>
<td>Main findings</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>---------</td>
<td>---------------</td>
</tr>
<tr>
<td>Jordan et al. [2011]²²</td>
<td>Prospective cohort mortality study.</td>
<td>Enrollees in the WTC Health Registry who were residents of New York City when enrolled in Registry. Study included 13,337 (3,188 women) rescue/recovery workers and 28,593 (16,733 women) survivors.</td>
<td>Using questionnaire data, they developed WTC-related exposure levels (high, intermediate, or low) separately for rescue/recovery workers and survivors.</td>
<td>Deaths were ascertained through linkage to death certificates in NYC vital records through 12/31/2009 and NDI through 12/31/2007.</td>
<td>All-cause SMRs were statistically significantly lower than that expected for rescue/recovery workers (SMR=0.45, 95% CI 0.38-0.53) and survivors (SMR=0.61, 95% CI 0.56-0.66). There were no statistically significantly elevated SMRs for any category of cancer examined, including cancer of female genital organs among Registry enrollees (SMR=0.82, 95% CI 0.49-1.28), rescue/recovery workers (SMR=0.67, 95% CI 0.08-2.43), or survivors (SMR=0.84, 95% CI 0.49-1.35). SMRs for uterine cancer were not provided.</td>
</tr>
<tr>
<td>Jordan et al. [2018]²³</td>
<td>Prospective cohort mortality study.</td>
<td>Update of the Jordan et al. (2011) study. Included the full cohort of WTC Health Registry enrollees, not only those living in New York City at enrollment, and adding five years of follow-up. This study included 29,280 (6,422 women) rescue/recovery workers and 39,643 (21,126 women) survivors.</td>
<td>Same as in the previous study.</td>
<td>Data were linked to the NDI through 12/31/2014.</td>
<td>Overall cancer SMRs were not elevated for rescue/recovery workers (SMR=0.94, 95% CI 0.84-1.05), but were statistically significantly elevated among survivors (SMR=1.14, 95% CI 1.06-1.24) when compared to the New York City population; no elevated SMRs were reported for all cancers using the general US population as reference. Cancer of the female genital organs were not statistically significantly elevated among rescue/recovery workers or survivors (SMR=0.67, 95% CI 0.27-1.39 and SMR=1.17, 95% CI 0.85-1.58, respectively). The authors also examined 119 sub-categories of the major causes of death, but only reported statistically significant results; uterine cancers were not among the reported causes of death, suggesting that the risk of uterine cancer was not statistically significantly elevated. No statistically significant elevations and no statistically significant trends were observed in the analyses of the association between 9/11-related exposures and overall cancer mortality. Dose-response findings were not provided for uterine cancer nor female genital organs.</td>
</tr>
</tbody>
</table>

Abbreviations: NDI – National Death Index, NYC – New York City, SIR – Standardized Incidence Ratio, SMR – Standardized Mortality Ratio, WTC – World Trade Center
Solan et al. [2013] conducted a cancer incidence study among workers, including 3,203 women, involved in rescue, recovery, and cleanup efforts at Ground Zero after 9/11, but who were not part of the FDNY. Cancer cases were identified through linkage with state tumor registries in New York, New Jersey, Connecticut, and Pennsylvania. Vital status was obtained through linkage with the National Death Index (NDI) and next-of-kin reports. The authors categorized self-reported exposures using occupation, extent of exposure to the dust cloud on 9/11, duration working at the site, and work on the debris pile during four time periods. They created an integrated exposure variable using a four-point scale (very high, high, intermediate, and low) based on total time spent working at Ground Zero, exposure to the dust cloud, and work on the debris pile. The standardized incidence ratio (SIR) (based on New York state rates for New York residents, state-specific incidence data for New Jersey and Connecticut residents; and national data for Pennsylvania residents) was elevated and statistically significant for all cancer sites combined (SIR=1.15; 95% confidence interval (CI), 1.06-1.25). Fewer than six cases of uterine cancer were observed, and no additional information was reported for this type of cancer. It is unknown how many cases of uterine cancer were identified. Furthermore, no SIRs were reported for uterine cancer nor were relative risks reported for the association between 9/11 integrated exposure variables (i.e., a 4-point scale based on total time spent working at Ground Zero, exposure to the dust cloud, and work on the debris pile) and uterine cancer.

Stein et al. [2016] conducted a mortality study among 28,918 general responders who worked or volunteered onsite in rescue, recovery, demolition, debris cleanup, or related duties, of which 4,286 were women. The authors ascertained cause of death by linkage to the National Death Index (NDI) through December 31, 2011. Exposure information was obtained through self-report in exposure assessment questionnaires. The authors categorized exposure as very high, high, intermediate, and low to reflect the intensity and duration of exposure to the dust, smoke, and debris. Overall cancer deaths were not elevated (standardized mortality ratio (SMR)=0.43, 95% CI 0.39-0.48). No cause specific SMRs were elevated, including cancers of the female genital organs (SMR=0.65, 95% CI 0.08-2.37). SMRs for uterine cancer were not reported. Mortality hazard ratios did not show a linear trend with exposure.

Li et al. [2012] conducted a cancer incidence study among enrollees in the WTC Health Registry who were residents of New York state on September 11, 2001 and had no history of cancer at the time of enrollment. Persons eligible for the study included 4,185 women involved in rescue/recovery and 18,922 women survivors not involved in rescue/recovery. Cancers were ascertained by linkage to 11 state cancer registries based on the state of residence of the cohort member. Expected numbers of cancers were based on New York state rates. The authors used qualitative descriptions of WTC exposures to classify exposure as high, intermediate, or low. They conducted separate analyses for rescue/recovery workers and for survivors and presented separate results for the period of enrollment through 2006 and 2007 through 2008. Among rescue/recovery workers, the SIR for all cancer sites combined was not statistically significantly elevated in any period of Registry enrollment (early period, SIR=0.94; 95% CI, 0.82-1.08; later period SIR=1.14; 95% CI, 0.99-1.30). Uterine cancer incidence was not elevated during the early period (five cases or less), SIR=0.97, 95% CI 0.2-2.83), and no cases were reported during the later period. Among survivors, no significantly increased incidence for cancer sites combined was observed in either period. Uterine cancer incidence was not elevated during the early or late periods (early: observed uterine cancers=16, SIR=1.01, 95% CI 0.58-1.65 and late: observed uterine cancers=14, SIR=1.01, 95% CI 0.55-1.69, respectively). Results of analyses to assess the risk of uterine cancer as a function of WTC exposure levels were not reported.

Li et al. [2016] updated the 2012 study [Li et al. 2012], adding three years of follow-up and using recalibrated exposure categories based on potential contaminants containing carcinogens. They also expanded the study population by including enrollees who lived in any of the 11 states selected for
cancer registry linkage between September 11, 2001 and December 31, 2011. The study included 5,015 female rescue/recovery workers and 18,845 women survivors not involved in rescue/recovery. The authors recalibrated exposure categories based on potential contaminants containing carcinogens. For rescue/recovery workers, they developed a WTC exposure matrix based on date of arrival, duration of work at the site, time working on the pile, and being near the WTC site. The analysis focused on cancers occurring from 2007 through 2011. Data were linked to 11 cancer registries as described by Li et al. [2012]. The overall cancer incidence was statistically significantly greater than the reference population of New York state among both rescue/recovery workers (SIR=1.11, 95% CI 1.03-1.20) and survivors (SIR=1.08, 95% CI 1.02-1.15). Uterine cancer incidence was not statistically significantly elevated among rescue/recovery workers nor among survivors (observed uterine cancers=8, SIR=0.82, 95% CI 0.35-1.62 and observed uterine cancers=37, SIR=1.03, 95% CI 0.72-1.41, respectively). Comparisons among exposure groups were not reported for uterine cancer.

Jordan et al. [2011] conducted a mortality study among the cohort of WTC Health Registry enrollees, including 3,188 rescue/recovery female workers and 16,733 women survivors living in New York City at time of enrollment. The authors used questionnaire data to develop 9/11-related exposure levels (high, intermediate, or low) separately for rescue/recovery workers and survivors. Deaths were ascertained through linkage to death certificates in New York City vital records through 12/31/2009 and NDI through 12/31/2007. All-cause SMRs were statistically significantly lower than that expected for rescue/recovery workers (SMR=0.45, 95% CI 0.38-0.53) and survivors (SMR=0.61, 95% CI 0.56-0.66). There were no statistically significantly elevated SMRs for any category of cancer examined, including cancer of female genital organs among all studied Registry enrollees (SMR=0.82, 95% CI 0.49-1.28), rescue/recovery workers (SMR=0.67, 95% CI 0.08-2.43), or survivors (SMR=0.84, 95% CI 0.49-1.35). SMRs for uterine cancer were not reported.

Jordan et al. [2018] updated their 2011 study by including the full cohort of WTC Health Registry enrollees (not only those living in New York City at enrollment, which was a requirement to be included in their 2011 study), and adding five years of follow-up. This study included rescue/recovery workers (6,422 women) and survivors (21,126 women). The authors conducted exposure assessment as in their earlier study. They linked their records to NDI through 12/31/2014. Overall cancer SMRs were not elevated for rescue/recovery workers (SMR=0.94, 95% CI 0.84-1.05), but were statistically significantly elevated among survivors (SMR=1.14, 95% CI 1.06-1.24) when compared with the New York City population; no elevated SMRs were reported for all cancers using the general U.S. population as reference. Cancer of the female genital organs were not statistically significantly elevated among rescue/recovery workers or survivors (SMR=0.67, 95% CI 0.27-1.39 and SMR=1.17, 95% CI 0.85-1.58, respectively). The authors also examined 119 sub-categories of the major causes of death, but only reported statistically significant results; uterine cancers were not among the reported causes of death, suggesting that the risk of uterine cancer was not statistically significantly elevated. No statistically significant elevations and no statistically significant trends were observed in the analyses of the association between 9/11-related exposures and overall cancer mortality.

Prospective cohort studies, like those described above, have the advantage that study participants are known to be disease-free at the beginning of the observation period when their exposure occurred; therefore, it is possible to establish the temporal sequence between exposure and outcome. However, since some slow-growing cancers become apparent only after long periods of time after exposure, it is possible that such cancers might have been present but undetected before September 11, 2001. In addition, all of the studies described above have had a relatively short period of follow-up since September 11, 2001. The studies discussed above might not have sufficient statistical power to detect excesses in uterine cancer due to their small size. This is especially a concern with studies of
rescue/recovery workers since those cohorts are only approximately 15 percent female. Another limitation of the studies reviewed is their overlap in participation, which limits the interpretation of consistency of findings among them. Approximately 20 percent of rescue/recovery workers enrolled in the WTC Health Program are also enrolled in the WTC Health Registry. These two cohorts also might be prone to selection bias, because enrollment in their respective programs was voluntary. For the WTC Health Registry cohort, it is possible that differential participation due to race/ethnicity, socioeconomic status, age, or their perception of being affected by the September 11, 2001 attacks, might have occurred. For the rescue/recovery worker cohort enrolled in the WTC Health Program, their health status, including their cancer diagnosis, might have prompted them to enroll. Study findings are available for both rescue/recovery workers and survivors. Another limitation is that only external comparisons were made. Thus, differences between the population of interest and the referent (control) group may have distorted risk estimates. It is likely that the 9/11 population is generally healthier than the referents used in existing studies.

The studies by Jordan et al. [2011] and Li et al. [2012] were updated by Jordan et al. [2018] and Li et al. [2016], respectively, and were therefore not further considered for evaluation. Of the four remaining studies, Jordan et al. [2018] and Stein et al. [2016] did not report findings for uterine cancer, and Solan et al. [2013] and Li et al. [2016] did not report elevated uterine cancer risks as a result of 9/11 exposures.

The Science Team concluded that the above studies do not provide consistent evidence that uterine cancer incidence or mortality is elevated among WTC responders and survivors. The Science Team concluded that the requirements of Method 1 were not met because collectively the studies do not demonstrate a potential to provide a basis for a decision on whether to add uterine cancer to the List.

B. Method 2 – Established Casual Association

Pursuant to Method 2, the Program explored whether there is an established casual association between uterine cancer and a condition already on the List of WTC-Related Health Conditions. A thorough review of the scientific literature found that estrogen-secreting tumors are associated with endometrial cancer, but these tumors are rare. The most common type of estrogen-secreting tumor are granulosa cell tumors of the ovary. Among women with granulosa cell tumors of the ovary, 5-10 percent also have endometrial cancer. Granulosa cell tumors of the ovary account for approximately 4–6 percent of all ovarian malignancies (i.e., approximately 4 cases of granulosa cell tumors of the ovary per million women per year).

Another type of estrogen-secreting tumor are adrenocortical cancers. Adrenocortical cancers are very rare (0.7–2.0 cases per million population per year), and those that are estrogen-secreting comprise a rare subset of all adrenocortical cancers. However, no scientific evidence was found linking estrogen-secreting adrenocortical cancer with uterine cancer. Instead, such estrogen-secreting adrenocortical cancers in women produce breast tenderness and dysfunctional uterine bleeding. A single case report was found that described a 32-year-old woman who had co-occurring adrenocortical cancer, uterine adenocarcinoma, and ovarian adenocarcinoma. The authors of that report conducted a literature search for similar cases but found none. The authors of that report could not explain why three tumors co-occurred in this patient.

Because estrogen-secreting tumors fall under the category of “rare cancers” in the List, uterine cancer can be added to the List only for members who have a certified estrogen-secreting tumor.
C. Method 3 – Review of Evaluations of Carcinogenicity in Humans

Pursuant to Method 3, the Science Team first reviewed the definitions of EDCs. The following authoritative organizations have defined EDCs as follows:\(^30\)

- **U.S. Environmental Protection Agency (EPA):** “An endocrine disruptor is an exogenous agent that interferes with the production, release, transport, metabolism, binding, action, or elimination of natural hormones in the body responsible for the maintenance of homeostasis and the regulation of developmental processes.”

- **European Union:** “An endocrine disruptor is an exogenous substance that causes adverse health effects in an intact organism, or its progeny, secondary to changes in endocrine function. A potential ED is a substance that possesses properties that might be expected to lead to endocrine disruption in an intact organism.”

- **World Health Organization:** “An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse effects in an intact organism, or its progeny, or (sub)populations.”

- **National Institute of Environmental Health Sciences (NIEHS):** “Many chemicals, both natural and man-made, may mimic or interfere with the body’s hormones, known as the endocrine system. Called endocrine disruptors, these chemicals are linked with developmental, reproductive, brain, immune, and other problems.”

The following agents are identified as common endocrine disruptors by NIEHS:\(^31\)

- **Bisphenol A (BPA)** — used to make polycarbonate plastics and epoxy resins, which are found in many plastic products including food storage containers.

- **Dioxins** — produced as a byproduct in herbicide production and paper bleaching, they are also released into the environment during waste burning and wildfires.

- **Perchlorate** — a by-product of aerospace, weapon, and pharmaceutical industries found in drinking water and fireworks.

- **Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS)** — used widely in industrial applications, such as firefighting foams and non-stick pan, paper, and textile coatings.

- **Phthalates** — used to make plastics more flexible, they are also found in some food packaging, cosmetics, children’s toys, and medical devices.

- **Phytoestrogens** — naturally occurring substances in plants that have hormone-like activity, such as genistein and daidzein that are in soy products, like tofu or soy milk.

- **Polybrominated diphenyl ethers (PBDE)** — used to make flame retardants for household products such as furniture foam and carpets.

- **Polychlorinated biphenyls (PCB)** — used to make electrical equipment like transformers, and in hydraulic fluids, heat transfer fluids, lubricants, and plasticizers.

- **Triclosan** — might be found in some anti-microbial and personal care products, like liquid body wash.

An additional EDC was identified by Mallozzi et al.,\(^32\) but not identified by NIEHS or others:
• **Cadmium and cadmium compounds** — Common industrial uses for cadmium today are in batteries, alloys, coatings (electroplating), solar cells, plastic stabilizers, and pigments.

The EDCs identified above that are also in the Inventory of 9/11 Agents are provided in Table 3 with the evaluation of carcinogenicity by IARC, NTP, and EPA. Although Method 3 only considers IARC and NTP, the EPA evaluations are included for greater awareness.

None of the 9/11 Agents identified as EDCs have been found by NTP, IARC, or EPA to be known to cause or be reasonably anticipated to cause uterine cancer.
<table>
<thead>
<tr>
<th>Name</th>
<th>IARC*</th>
<th>NTP</th>
<th>EPA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dioxins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dioxins</td>
<td>Monograph 69 [1997]</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,3,7,8-Tetrachlorodibenzodioxin</td>
<td>Supplement 7, Monographs 69, 100F [2012]</td>
<td>Group 1 [lung, soft tissue, leukemia and lymphoma, all cancer sites (combined)]’ 1999 Known to be a human carcinogen 2012 Cancer assessment is underway</td>
<td></td>
</tr>
<tr>
<td>1,2,3,7,8-Pentachlorodibenzodioxin</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,7,8-Hexachlorodibenzodioxin</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,6,7,8-Hexachlorodibenzodioxin</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,7,8,9-Hexachlorodibenzodioxin</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,6,7,8-Heptachlorodibenzodioxin</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,6,7,8,9-Octachlorodibenzodioxin</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,3,7,8-Tetrachlorodibenzofuran</td>
<td>Monograph 69 [1997]</td>
<td>Dibenzofurans, except 2,3,4,7,8-pentachlorodibenzofuran, are Group 3 Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,3,4,7,8-Pentachlorodibenzofuran</td>
<td>Monograph 100F [2012]</td>
<td>Overall evaluation upgraded to Group 1 based on mechanistic and other relevant data</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,7,8-Hexachlorodibenzofuran</td>
<td>Monograph 69 [1997]</td>
<td>Group 3</td>
<td>Not listed</td>
</tr>
<tr>
<td>Name</td>
<td>IARC*</td>
<td>NTP</td>
<td>EPA</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>1,2,3,6,7,8-Hexachlorodibenzofuran</td>
<td>Monograph 69 [1997] Group 3</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,7,8,9-Hexachlorodibenzofuran</td>
<td>Monograph 69 [1997] Group 3</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,3,4,6,7,8-Hexachlorodibenzofuran</td>
<td>Monograph 69 [1997] Group 3</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,6,7,8-Heptachlorodibenzofuran</td>
<td>Monograph 69 [1997] Group 3</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,7,8,9-Heptachlorodibenzofuran</td>
<td>Monograph 69 [1997] Group 3</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3,4,6,7,8,9-Octachlorodibenzofuran</td>
<td>Monograph 69 [1997] Group 3</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td><strong>Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS)</strong></td>
<td>Only perfluorooctanoic acid (PFOA) listed</td>
<td>Not listed</td>
<td>2020 Systematic review protocol released for IRIS assessment of multiple PFAS</td>
</tr>
<tr>
<td>Perfluorodecanoic acid</td>
<td>Not listed</td>
<td>Not listed</td>
<td>2020 Systematic review protocol</td>
</tr>
<tr>
<td>Perfluorohexanesulfonate acid</td>
<td>Not listed</td>
<td>Not listed</td>
<td>2020 Systematic review protocol</td>
</tr>
<tr>
<td>Perfluoroisobutylene</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>Perfluoroundecanoic acid</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>Perfluorononanoic acid</td>
<td>Not listed</td>
<td>Not listed</td>
<td>2020 Systematic review protocol</td>
</tr>
<tr>
<td><strong>Phthalates</strong></td>
<td>Only benzyl butyl phthalate listed</td>
<td>Only di(2-ethylhexyl) phthalate listed (not on inventory)</td>
<td>Only those listed below</td>
</tr>
<tr>
<td>Diisobutyl phthalate</td>
<td>Not listed</td>
<td>Not listed</td>
<td>IRIS assessment suspended/discontinued</td>
</tr>
<tr>
<td>Name</td>
<td>IARC*</td>
<td>NTP</td>
<td>EPA</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>----------------------------</td>
<td>--------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Dibutyl phthalate</td>
<td>Not listed</td>
<td>Not listed</td>
<td>1988 D (Not classifiable as to human carcinogenicity)</td>
</tr>
<tr>
<td>Diethyl phthalate</td>
<td>Not listed</td>
<td>Not listed</td>
<td>1988 D (Not classifiable as to human carcinogenicity)</td>
</tr>
<tr>
<td>Dicyclohexyl phthalate</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td><strong>Polybrominated diphenyl ethers</strong></td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',4,4'-Tetrabromodiphenyl ether</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,2,3-tribromo-4-(2,4-dibromophenoxy)benzene</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',4,4',5-Pentabromodiphenyl ether</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>1,3,5-Tribromo-2-(2,4-dibromophenoxy)benzene</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',4,4',5,5'-Hexabromodiphenyl ether</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',4,4',5,6'-Hexabromodiphenyl ether</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',3,4,4',5,6-heptabromodiphenyl ether</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>Pentabromophenyl ether</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,3,3',4',6- Pentachlorobiphenyl</td>
<td>Not listed</td>
<td>Not listed</td>
<td>1996 B2 (probable human carcinogen)</td>
</tr>
<tr>
<td>3,3',4,4',5-Pentachlorobiphenyl</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',3,4,4',5'-Hexachlorobiphenyl</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>Name</td>
<td>IARC*</td>
<td>NTP</td>
<td>EPA</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------------</td>
<td>------------</td>
<td>----------------</td>
</tr>
<tr>
<td>2,2',4,4',5,5'-Hexachlorobiphenyl</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td>2,2',3,4,4',5,5'-Heptachlorobiphenyl</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
<tr>
<td><strong>Cadmium and cadmium compounds</strong></td>
<td><strong>Monograph 58, Monograph 100C [2012]</strong></td>
<td><strong>Group 1 [lung, prostate, kidney]</strong></td>
<td><strong>1987</strong></td>
</tr>
<tr>
<td></td>
<td><strong>2016</strong></td>
<td><strong>Known to be a human carcinogen</strong></td>
<td><strong>B1 (probable human carcinogen)</strong></td>
</tr>
</tbody>
</table>

*IARC classifies agents as: Group 1 - Carcinogenic to humans; Group 2A - Probably carcinogenic to humans; Group 2B - Possibly carcinogenic to humans; and Group 3 - Not classifiable as to its carcinogenicity to humans.

†Square brackets include the organs for which the agents have *sufficient or limited* evidence of carcinogenicity in humans.33
The WTC Health Program identified studies on carcinogenicity of TCDD/dioxin and cadmium that were published after the IARC evaluations were conducted. The findings of these studies are shown in Tables 4 and 5, respectively. No new evidence on uterine cancer was identified.

It is relevant to note that TCDD/dioxin is classified by IARC as having sufficient evidence of carcinogenicity in humans for all cancers combined. However, IARC does not interpret this as meaning that every cancer may be caused by TCDD.

Table 4. Studies of TCDD and cancer published after the latest IARC Monograph (2012):

<table>
<thead>
<tr>
<th>Study design</th>
<th>Study population</th>
<th>Reference population(s)</th>
<th>Outcome, uterine cancer risk estimate</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ecological</td>
<td>Michalovce District, the Slovak Republic (~ 112,000 inhabitants) and Uherske Hradiste, the Czech Republic (146,000 inhabitants)</td>
<td>Slovak Republic (~ 5 M inhabitants) and the Czech Republic (10,3 M inhabitants)</td>
<td>Cancer incidence, NR</td>
<td>Bencko et al. [2009]34</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>1,615 workers who worked 1 or more days in a department with potential TCDD exposure</td>
<td>US population</td>
<td>Mortality, NR</td>
<td>Collins et al. [2009]35</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>Subjects resident and those who migrated into (or newborn in) the area in the 10-year period after the Seveso accident in three contaminated zones with decreasing TCDD soil levels: 723 (high), 4,821 (medium), 31,643 (low)</td>
<td>181,574 residents of the surrounding non-contaminated zone</td>
<td>RR (95% CI) = 1.24 (0.17-8.82) (high exposure); 0.6 (0.19-1.87) (medium exposure); 0.73 (0.49-1.10) (low exposure)</td>
<td>Pesatori et al. [2009]36</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>777 Ranch Hand veterans exposed to Agent Orange, contaminated with TCDD</td>
<td>737 comparison veterans</td>
<td>Cancer incidence, men only</td>
<td>Buffler et al. [2011]37</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>2122 pentachlorophenol (PCP) production workers from four plants exposed to PCP and to polychlorinated dibenzo-p-dioxin and dibenzofuran contaminants of PCP production.</td>
<td>US population</td>
<td>Mortality, NR</td>
<td>Ruder and Yiin [2011]38</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>180,639 Korean Vietnam war veterans (no indication if women were included)</td>
<td>7,973 low exposed veterans</td>
<td>Mortality, NR</td>
<td>Yi et al. [2014]39</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>180,251 Korean Vietnam veterans (no indication if women were included)</td>
<td>Low and no-exposed veterans</td>
<td>Cancer incidence, NR</td>
<td>Yi et al. [2014]40</td>
</tr>
<tr>
<td>Study design</td>
<td>Study population</td>
<td>Reference population(s)</td>
<td>Outcome, uterine cancer risk estimate</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td>45 cases from 2 mortality studies</td>
<td>Pooled reference populations.</td>
<td>Mortality, NR</td>
<td>Xu et al. [2016]</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>1,599 men and women working at a New Plymouth, New Zealand plant producing the herbicide 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) with TCDD as a contaminant</td>
<td>New Zealand population</td>
<td>Mortality, SMR (95% CI) = 0.0 (0.0-17.78)</td>
<td>McBride et al. [2018]</td>
</tr>
<tr>
<td>10-year period cancer prevalence ratio study</td>
<td>631 endometrial cancer cases diagnosed between 2010-2020 among Vietnam War era deployed Veterans</td>
<td>Non-Vietnam War deployed veterans</td>
<td>Adjusted period prevalence ratio (95% CI) = 0.72 (0.33-1.11)</td>
<td>Hastings [2021]</td>
</tr>
</tbody>
</table>

Abbreviations: NR – uterine cancer risk not reported; RR – relative risk; SMR – standardized mortality ratio.

Only the Pesatori et al. [2009] study reported an elevated, albeit not statistically significant, risk of uterine cancer associated with TCDD exposure. Study participants were exposed to very high levels of TCDD as a result of a chemical explosion close to their residence. TCDD levels in serum collected at the time of the accident were shown to be of similar magnitude to those reported in 2,4,5-trichlorophenol production workers, and some were among the highest ever reported. An analysis of 232 stored samples from girls who were age 0-10 at the time of the incident showed a median TCDD concentration that ranged from 123 ppt for those age >5–10 years to 288 for those age >0-2 years, with higher concentrations among those in the most contaminated zone: 322 ppt for those age >5-10 years to 553 ppt for those age >0-2 years. In comparison, the median TCDD serum concentration in a WTC cohort of 110 adolescents at the time of the attack was 10 ppt, 12 years after exposure. In this study, mean TCDD levels were 14.2 pg/g lipid among 60 9/11-exposed study participants and 2.10 pg/g lipid among 50 non-exposed participants.
Table 5. Studies of cadmium and cancer published after the latest NTP evaluation (2016):

<table>
<thead>
<tr>
<th>Study design</th>
<th>Study population</th>
<th>Reference population(s)</th>
<th>Outcome, uterine cancer risk estimate</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prospective cohort</td>
<td>7348 individuals from the Jinzu River basin, the heaviest Cd-polluted area in Japan</td>
<td>2098 residents of non-polluted areas</td>
<td>Adjusted HR for death from all cancers or from renal and uterine cancers were statistically significantly higher in subjects with proteinuria, glucosuria, and glucoproteinuria</td>
<td>Nishijo et al. [2018]</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>229 individuals from the Taisi Village in Taiwan living nearby a petrochemical complex</td>
<td>1333 individuals from the Dacheng Township, and 372 individuals from the Zhutang Township</td>
<td>All cancer IRR higher in Taisi than non-exposed populations, NR</td>
<td>Chen et al. [2018]</td>
</tr>
<tr>
<td>Nested case-control</td>
<td>1,200 cancer cases who, at some time between the years 1979–2004 lived within a 2 km radius of a glassworks emission source in Sweden</td>
<td>7,000 cancer-free control individuals</td>
<td>NR</td>
<td>Helmfrid et al. [2019]</td>
</tr>
<tr>
<td>Prospective cohort</td>
<td>1161 men and 1812 women from non-Cd polluted areas in Japan</td>
<td>Individuals with urinary Cd levels below limit of detection</td>
<td>Mortality, one uterine cancer case observed, NR</td>
<td>Watanabe et al. [2020]</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>Copper metallurgy waste workers (exposed to metals, included Cd)</td>
<td>Not reported in abstract</td>
<td>Article in Russian. Mortality, NR among cancers elevated in women</td>
<td>Adrianovsky et al. [2020]</td>
</tr>
<tr>
<td>Prospective cohort</td>
<td>26,056 participants from NHANES</td>
<td>Not indicated</td>
<td>Cadmium in urine was associated with all cancer mortality, NR</td>
<td>Duan et al. [2020]</td>
</tr>
</tbody>
</table>
IV. Additional Considerations

In addition to the three methods outlined above, a type of cancer may be added to the List if the STAC provides a reasonable basis for adding it. The Administrator has requested a STAC recommendation regarding whether 9/11 exposures have a causal association with uterine cancer.

The Zadroga Act allows the STAC 90 days, with potential extension up to 180 days, to give its recommendation to the Administrator. The STAC may consider any scientific evidence it deems relevant to determining whether or not there is sufficient support for the addition of uterine cancer to the List of WTC-Related Health Conditions. As outlined below, the Science Team has accumulated additional information that the STAC may wish to consider in its deliberations.

1. Mechanisms of endometrial cancer development

The review by Banno et al. [2014] describes the currently proposed mechanisms of carcinogenesis in endometrial cancer. These mechanisms include estrogen, an abnormal mismatch repair (MMR) system, genetic abnormalities, and aberrant methylation of DNA and microRNA. The mechanisms of Type I endometrial cancer development (which accounts for 80 percent of all endometrial cancers) do not markedly differ from those at other cancer sites. The mechanisms of type II endometrial cancers remain largely unknown. What follows is a summary of the commonalities in mechanisms for uterine (type I and II) and other cancers.

- The mismatch repair (MMR) system is responsible for repairing base mismatches that arise during DNA replication. Aberrations in MMR genes are involved in carcinogenesis of type I endometrial cancer. MMR genes are also causative genes in Lynch syndrome (hereditary nonpolyposis colorectal cancer), a typical familial tumor with autosomal dominant inheritance.

- Gene mutations found in type I endometrial cancer include those in PTEN, β-catenin and K-ras. PTEN inactivation is also found in malignant melanoma, brain tumors, and endometrial, ovarian,
thyroid, breast, and prostate cancers. β-catenin and K-ras mutations are found in various human cancers.

- Mutations in type II endometrial cancer are thought to be linked to the oncogene HER-2/neu and tumor suppressor gene p53. Mutations of the HER-2/neu gene are also found in breast and ovarian cancers. A p53 gene mutation is the most frequent mutation in human cancer.

- RB and cyclin might also be involved in the carcinogenesis of endometrial cancer. RB gene mutations have been found in small cell lung, bladder, and esophageal cancers.

- Many tumor suppressor genes in cancer cells are inactivated by aberrant DNA methylation in different cancer pathways. An example is RSK4 expression, that has been shown to be downregulated by methylation in atypical endometrial cancer, as well as in rectal, breast and kidney cancers. Another example is CHFR downregulation by aberrant hypermethylation that increases the paclitaxel sensitivity of gastric and endometrial cancers.

- microRNAs (miRNAs) are short noncoding RNAs that regulate gene expression. miRNAs that inhibit DNA methylation in cancers are referred to as tumor suppressor miRNAs (TSmiRNA). One microRNA, miR-152 is also a TS-miRNA in endometrial cancer. miR-152 methylation levels are also changed in acute lymphoblastic leukemia, gastrointestinal cancer, and cholangiocarcinoma.

2. Other evidence from studies of uterine cancer from exposure to the 9/11 agents TCDD, PCBs, cadmium, asbestos, and chloroethane:

a. The retrospective cohort study by Pesatori et al. [2009] among residents and those who migrated into the area in the 10-year period after the Seveso accident. The study compared people in three contaminated zones with decreasing TCDD soil levels: 723 (high TCDD soil levels), 4,821 (medium), 31,643 (low) with 181,574 residents of the surrounding non-contaminated zone. Incident cancer cases were ascertained through 120 hospital-network of the Lombardy region between 1977 and 1996. Sex-, age-, and period-adjusted rate ratios (RR) and 95% confidence intervals (95% CI) for uterine cancer were: RR (95% CI) = 1.24 (0.17-8.82) (high exposure); 0.6 (0.19-1.87) (medium exposure); 0.73 (0.49-1.10) (low exposure).

b. The findings by Kogevinas et al. [1997] from the International Cohort Study. This is a retrospective mortality study of 21,863 male and female workers exposed to phenoxy herbicides, chlorophenols, and dioxins in 12 countries. The authors reconstructed exposure using job records, company exposure questionnaires, and serum and adipose tissue dioxin levels. Follow-up period varied in each cohort; overall, it extended from 1939 to 1992. The study found an SMR for uterine cancer among workers exposed to TCDD or higher chlorinated dioxins of 3.41 (95% CI 0.7–9.96).

c. The prospective population-based Swedish Mammography Cohort study of dietary PCB exposure, by Donat-Vargas et al. [2016]. This study included 36,777 cancer-free women at baseline. Validated estimates of dietary PCB exposure were obtained via a food frequency questionnaire. Incident cancer cases were ascertained through register linkage. The study found a non-statistically significant increased risk of endometrial cancer (adjusted RR in the highest tertile of PCB exposure=1.21, 95% CI: 0.73–2.01; \( p_{\text{trend}}=0.54 \)).

d. The study by Akesson et al. [2008], also conducted in the population-based Swedish Mammography Cohort. This study is a prospective cohort of 30,210 postmenopausal women who were cancer-free at baseline (1987) and who completed a food frequency questionnaire at baseline and in 1997. The authors estimated dietary cadmium intake based on the questionnaire...
data and cadmium content in all foods. They found an adjusted RR=1.39 (95% CI 1.04–1.86, $p_{\text{trend}}$=0.019) of post-menopausal endometrial cancer in the higher tertile of dietary cadmium consumption.

e. The retrospective mortality study by Magnani et al. [2008] in a cohort of 3,434 Italian asbestos cement workers (2657 men and 777 women).\textsuperscript{58} The authors ascertained vital status and cause of death though registrar offices; diagnoses for five out of 15 cases observed could not be confirmed. When compared with the population of Piedmont, an excess uterine cancer mortality was observed among female workers (SMR=25.7, 95% CI 1.44-4.24). The number of uterine cancer cases increased after at least 10 years of latency, but no trend by duration of exposure was observed. In contrast, a retrospective cancer incidence study by Reid et al. [2009] followed up 2,552 women, residents of Wittenoom, Australia, and 416 workers of the local asbestos company.\textsuperscript{59} When compared with the Western Australian population, no increased incidence of uterine cancer was observed. With the exception of intensity of exposure, risk decreased with increases in time since first exposure, year of arrival, age of first exposure, and duration of exposure.

f. The study by Holder [2008], who exposed male and female F344 rats and B6C3F1 mice (50/sex/group) chronically to either 0 or 15,000 ppm chloroethane gas for 6 h/day, 5 days/week for 102 weeks (rats) or 100 weeks (mice).\textsuperscript{60} Chloroethane was associated with uterine cancer in mice (but not rats). The author indicates that the mechanism appears to be through chloroethane-stimulated adrenal production of corticosteroids, which adversely promotes endometrial cells to cancer in mice—a mechanism that is also observed in humans.

3. Sex Disparities in Occupational Cohort Studies, and other cancers causally associated with EDCs

Most studies of exposures to EDCs have been conducted in occupational cohorts, which included a small number of women or no women at all. Furthermore, there are other cancers that are associated with EDCs (e.g., breast, prostate, and ovarian cancers).

In addition, the following evidence from Table 3 shows that other cancers are causally associated with endocrine disrupting agents included in the Inventory of 9/11 agents:

- **2,3,7,8-Tetrachlorodibenzodioxin**, classified by IARC in Group 1 (carcinogenic to humans).\textsuperscript{61} It is an agent with limited evidence in humans for cancers of the lung, soft tissue sarcoma, and non-Hodgkin lymphoma, and sufficient evidence in humans for all cancer sites (combined).\textsuperscript{33} It is also listed as a Known to Be a Human Carcinogen on NTP’s Fourteenth Report on Carcinogens.\textsuperscript{62}

- **2,3,4,7,8-Pentachlorodibenzofuran**, classified by IARC in Group 1.\textsuperscript{61} There is no evidence in humans of its carcinogenicity; however, there is sufficient evidence in experimental animals, as well as mechanistic and other relevant data that support this classification.

- **Perfluorooctanoic acid**, classified by IARC in Group 2B (possibly carcinogenic to humans).\textsuperscript{63} It is an agent with limited evidence in humans for cancers of the kidney and testis.\textsuperscript{33}

- **Polychlorinated biphenyls (PCBs)**, classified by IARC in Group 1.\textsuperscript{64} PCBs have sufficient evidence in humans for skin cancer (melanoma) and limited evidence for breast cancer, and leukemia and lymphoma. They are considered Reasonably Anticipated to Be a Human Carcinogen by NTP and classified in Group B2 (probable human carcinogen, based on sufficient evidence of carcinogenicity in animals) by EPA.\textsuperscript{62, 65}
• **Cadmium and cadmium compounds**, classified by IARC in Group 1.66 Cadmium and its compounds have sufficient evidence in humans for lung cancer and limited evidence for cancers of the prostate and kidney.33

V. **WTC Health Program’s Actions after Receipt of the STAC Recommendation**

After receiving the recommendations from the STAC, the Administrator will evaluate the Committee’s advice and any further assessment by the Science Team. Not later than 90 days after receipt of the STAC’s recommendation, the Administrator will publish in the *Federal Register* a proposed rule with respect to such recommendation or a determination not to propose such a proposed rule and the basis for such determination.
VI. References


